Micro Pharmaceuticals

Parnax Lab Ltd.

PARNAXLAB

₹105.4

-1.95% (-2.1)

Market Cap

₹123 Cr.

P/E

10.72

Parnax Lab Ltd.

Price
Growth Table
Balance Sheet
Profit & Loss
Cash Flow
Cash Flow Analysis
Ratios
Quarterly Results
Reverse DCF

FAQs on Parnax Lab Ltd. Shareprice

Has the share price of Parnax Lab grown faster than its competition?

Parnax Lab has given better returns compared to its competitors.
Parnax Lab has grown at ~10.17% over the last 1yrs while peers have grown at a median rate of -21.02%

Is Parnax Lab stock expensive?

Parnax Lab is not expensive.
Latest PE of Parnax Lab is 10.72, while 3 year average PE is 22.23.
Also latest EV/EBITDA of Parnax Lab is 6.76 while 3yr average is 6.93.

View FAQ's On Business

Growth Table

Parnax Lab Ltd.
Sotac Pharmaceutical
Loading...
Lactose India
Loading...

In %	1yr	2yr	3yr	4yr	5yr	6yr	7yr	8yr	9yr	10yr
Share Price CAGR	2.88	29.72	0.72	39.67	44.12	23.61	11.89	7.43	14.50	16.19
TTM EPS CAGR	17.53	14.17	7.01	—	—	8.95	16.88	6.47	11.34	4.75
Sales CAGR	-0.52	5.84	4.82	20.34	14.52	9.52	8.65	8.90	11.34	6.13
PAT Margin (Abs Growth)	-0.05	0.03	5.50	8.16	2.06	4.10	1.21	1.58	0.98	1.54
PE CAGR	-6.26	14.75	-5.25	—	—	13.77	-3.46	0.51	3.50	11.14
CFO CAGR	-24.07	36.30	36.02	16.08	12.74	3.54	-0.15	20.87	—	—

* Share price and PE growth are updated everyday. All other fields are as of latest financial year end. EPS adjusted for bonus and splits.

Balance Sheet

Parnax Lab Ltd.
Sotac Pharmaceutical
Loading...
Lactose India
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Assets	79.40	85.53	87.37	94.68	107	106	153	145	189	190
Non Current Assets	48.35	54.47	50.23	57.07	59.86	65.14	75.53	80.08	109	121
Net Block	37.85	47.32	43.70	51.06	57.68	59.66	71.95	76.81	89.48	87.46
Capital Work in Progress	2.44	0.00	0.00	0.14	2.91	4.91	3.34	2.33	20.61	0.80
Intangible Assets Under Development	—	—	—	—	—	—	—	—	—	—
Long Term Investments	0.91	0.34	0.23	0.21	0.22	0.22	0.22	0.16	0.16	0.16
Current Assets	30.57	30.87	36.46	36.90	41.87	35.50	71.03	57.32	71.81	68.34
Inventory	6.63	7.94	7.67	8.47	11.15	10.79	19.93	21.69	29.93	25.77
Accounts Receivable	19.42	18.66	18.66	19.18	23.08	16.71	38.08	27.89	32.56	30.77
Short Term Investments	—	—	—	—	—	—	—	—	—	—
Cash & Bank Balances	0.38	1.13	1.61	0.60	1.30	1.27	5.78	2.78	1.88	2.68
Liabilities	79.40	85.53	87.37	94.68	107	106	153	145	189	190
Shareholders Funds	27.64	31.37	32.51	35.73	32.80	32.54	48.19	62.15	71.57	83.10
Share Capital	8.50	8.50	8.50	8.50	8.50	8.50	9.81	11.49	11.49	11.49
Reserves	19.14	22.86	24.01	27.23	24.29	24.04	36.55	50.67	60.09	71.61
Non Current Liabilities	22.81	17.65	17.60	22.58	21.83	19.26	24.21	19.77	35.24	32.24
Secured Loans	13.72	12.57	11.70	16.19	19.12	13.94	17.41	12.02	21.05	—
Unsecured Loans	8.59	4.51	5.00	5.39	0.03	0.03	—	—	—	17.99
Current Liabilities	28.90	36.45	37.19	36.29	52.46	54.37	80.98	63.04	81.83	74.33
Accounts Payable	3.09	7.67	7.68	7.26	10.86	6.23	22.08	14.76	22.18	21.35
Short Term Loans	13.05	15.65	15.03	15.69	28.11	36.43	42.70	33.27	43.21	42.65

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

Increase
Decrease
Total

No data available.

*Data is as of latest FY end

Profit & Loss

Parnax Lab Ltd.
Sotac Pharmaceutical
Loading...
Lactose India
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Sales	71.18	94.81	105	109	95.31	90.06	163	168	189	188
Operating Expenses	61.21	82.41	95.76	98.56	88.89	80.11	140	145	165	161
Raw Material	37.10	49.85	55.12	52.83	46.18	41.31	91.70	89.19	105	93.85
Material Cost (%)	53.11	52.67	52.04	48.46	47.50	46.37	54.99	52.99	54.48	50.63
Employee Cost	7.46	9.22	11.68	13.06	14.08	13.68	17.43	20.05	23.72	24.43
Power & Fuel Cost	2.11	3.27	2.99	3.13	4.12	4.29	5.24	5.37	6.37	—
Operating Profit	9.97	12.40	9.74	10.22	6.43	9.95	23.03	22.99	23.54	26.76
Other Income	0.70	0.99	1.34	2.11	0.67	0.21	0.33	0.77	0.82	1.68
OPM (%)	14.00	13.08	9.24	9.40	6.74	11.04	14.13	13.72	12.48	14.26
Depreciation and Amortisation	2.90	3.75	3.74	3.82	4.46	5.16	5.87	6.53	6.96	7.38
Interest	4.29	4.92	4.32	3.89	4.60	5.08	5.23	4.95	5.35	5.39
Profit Before Tax	3.48	4.71	3.02	4.62	-1.97	-0.08	12.26	12.28	12.05	15.67
Tax	0.97	1.02	1.97	1.31	0.95	0.28	4.01	3.65	2.42	4.13
Net Profit	2.50	3.68	1.05	3.30	-2.91	-0.36	8.24	8.62	9.61	11.54
Number of shares(Crs)	0.85	0.85	0.85	0.85	0.85	0.85	0.98	1.15	1.15	—
Dividend Payout Ratio(%)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

TTM Values as of Mar 2025

Cash Flow

Parnax Lab Ltd.
Sotac Pharmaceutical
Loading...
Lactose India
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Sep'24
Cash from Operating Activity	3.49	16.05	12.88	8.72	8.75	6.31	8.55	20.91	15.88	22.07
Profit Before Tax	3.48	4.71	3.02	4.62	-1.97	-0.08	12.26	12.28	12.05	16.00
Adjustments	3.04	8.78	9.60	7.70	8.97	10.23	11.05	11.58	11.86	12.57
OCF Before Working Capital	6.52	13.50	12.62	12.32	7.00	10.14	23.32	23.86	23.91	28.58
Working Capital Changes	-1.90	3.91	0.91	-2.21	2.81	-3.08	-14.53	-0.09	-5.40	-3.55
Taxes Paid	-1.13	-1.35	-0.65	-1.40	-1.07	-0.76	-0.24	-2.86	-2.64	-2.95
Cash from Investing Activity	-6.18	-10.22	-5.18	-11.15	-13.33	-6.56	-16.50	-9.92	-31.52	-32.08
Net Fixed Assets Purchased	-6.13	-10.84	-5.23	-11.25	-10.33	-4.48	-17.82	-11.03	-13.73	-27.79
Fixed Assets Purchased	-6.13	-10.84	-5.23	-11.32	-10.36	-4.54	-17.83	-11.28	-14.21	-28.41
Fixed Assets Sold	—	—	—	0.08	0.03	0.07	0.01	0.25	0.48	0.62
Investment Purchased	-0.05	—	-0.01	—	-0.27	-0.17	-0.33	-0.08	—	—
Investment Sold	—	0.57	—	0.02	—	—	—	0.06	0.08	—
Interest Recieved	—	0.05	0.06	0.07	0.07	0.16	0.18	0.11	0.42	0.49
Dividends Recieved	—	—	—	0.01	0.02	0.00	0.00	0.20	—	—
Subsidiary Investments	—	—	—	—	—	—	—	—	—	—
Cash from Financing Activity	0.72	-5.45	-7.18	1.42	5.03	0.05	12.13	-14.07	14.82	9.29
Proceeds From Shares	—	—	—	—	—	—	—	—	—	—
Net Long Term Borrowings	-0.24	0.00	0.00	0.00	0.00	0.00	3.43	-5.39	9.03	7.97
Proceeds From Borrowings	4.45	—	—	—	—	—	3.43	—	9.03	7.97
Repayment From Borrowings	-4.69	—	—	—	—	—	—	-5.39	—	—
Interest Paid	—	-4.48	-3.76	-3.27	-4.60	-5.08	-5.23	-4.95	-5.35	-5.64
Dividend Paid	—	—	—	—	—	—	—	—	—	—
Net Cash Flow	-1.97	0.38	0.53	-1.01	0.44	-0.21	4.18	-3.08	-0.82	-0.71
Opening Cash & Cash Equivalents	2.36	0.05	0.43	0.96	-0.05	0.39	0.18	4.36	1.28	—
Effect of FX	—	—	—	—	—	—	—	—	—	—
Closing Cash & Cash Equivalents	0.38	0.43	0.96	-0.05	0.39	0.18	4.36	1.28	0.46	—
Net Capex (est)	6.13	10.84	5.23	11.25	10.33	4.48	17.82	11.03	13.73	27.79
Free Cash Flow (est)	-2.64	5.21	7.65	-2.53	-1.59	1.83	-9.28	9.88	2.14	-5.71

Cash Flow Analysis

Increase
Decrease
Total

No data available.

Ratios

= Dominant Factor

Parnax Lab Ltd.
Sotac Pharmaceutical
Loading...
Lactose India
Loading...

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Operational Ratios
Quick Ratio	1.00	0.83	0.63	0.77	0.78	0.59	0.45	0.63	0.57	0.51
Liquid Assets (Crs)	30.93	23.94	23.00	28.79	28.42	30.72	24.71	51.10	35.64	41.88
Current Liabilities (Crs)	31.02	28.90	36.45	37.19	36.29	52.46	54.37	80.98	63.04	81.83
Current Ratio	1.22	1.06	0.85	0.98	1.02	0.80	0.65	0.88	0.91	0.88
Current Assets (Crs)	37.96	30.57	30.87	36.46	36.90	41.87	35.50	71.03	57.32	71.81
Current Liabilities (Crs)	31.02	28.90	36.45	37.19	36.29	52.46	54.37	80.98	63.04	81.83
Interest Coverage Ratio	2.24	1.81	1.96	1.70	2.19	0.57	0.98	3.34	3.48	3.25
EBIT (Crs)	9.84	7.78	9.63	7.35	8.51	2.63	5.00	17.49	17.23	17.40
Interest Expenses (Crs)	4.40	4.29	4.92	4.32	3.89	4.60	5.08	5.23	4.95	5.35
Fixed Asset Turnover	1.88	1.21	1.86	2.09	1.76	1.31	1.13	1.68	1.55	1.49
Net Sales (Crs)	103	71.18	94.81	105	109	95.31	90.06	163	168	189
Fixed Assets (Crs)	54.55	58.88	51.07	50.47	61.65	72.73	79.40	97.25	108	127
Cash Conversion Cycle	61.17	107	77.26	60.99	62.11	45.48	50.42	38.08	41.44	42.80
Inventory Days	40.41	35.01	28.05	27.01	27.08	37.57	44.46	34.39	45.31	49.92
Days Receivable	85.55	110	73.29	64.56	63.50	80.93	80.64	61.33	71.83	58.46
Days Payable	64.80	38.03	24.08	30.58	28.47	73.02	74.68	57.63	75.70	65.58
Debt to Equity Ratio	1.63	1.51	1.26	1.13	1.17	1.54	1.71	1.36	0.82	0.99
Total Debt (Crs)	41.06	41.78	39.49	36.63	41.94	50.49	55.62	65.47	50.90	71.06
Shareholders Equity (Crs)	25.14	27.64	31.37	32.51	35.73	32.80	32.54	48.19	62.15	71.57
Free Cash Flow/Sales (%)	-3.94	-3.72	5.50	7.25	-2.33	-1.66	2.04	-5.69	5.89	1.14
Free Cash Flow(est) (Crs)	-4.05	-2.64	5.21	7.65	-2.53	-1.59	1.83	-9.28	9.88	2.14
Net Sales (Crs)	103	71.18	94.81	105	109	95.31	90.06	163	168	189
Profitability Ratios
Gross Margin (%)	34.88	46.89	47.33	47.96	51.54	52.50	53.63	45.01	47.01	45.52
Op Profit Margin (%)	11.70	14.00	13.08	9.24	9.40	6.74	11.04	14.13	13.72	12.48
Operating Profit (Crs)	12.83	10.67	13.39	11.09	12.33	7.09	10.16	23.36	23.76	24.36
Net Sales (Crs)	103	71.18	94.81	105	109	95.31	90.06	163	168	189
Net Profit Margin (%)	4.13	3.51	3.89	1.00	3.03	-3.06	-0.40	5.06	5.14	5.09
Net Profit (Crs)	4.25	2.50	3.68	1.05	3.30	-2.91	-0.36	8.24	8.62	9.61
Net Sales (Crs)	103	71.18	94.81	105	109	95.31	90.06	163	168	189
ROCE (%)	18.99	15.40	19.63	14.64	14.57	4.82	9.63	24.13	21.01	16.27
EBIT (Crs)	9.84	7.78	9.63	7.35	8.51	2.63	5.00	17.49	17.23	17.40
Capital Employed (Crs)	51.80	50.50	49.08	50.18	58.39	54.70	51.88	72.49	82.03	107
Return on Assets (%)	5.13	3.15	4.31	1.21	3.48	-2.72	-0.34	5.37	5.94	5.09
Net Profit (Crs)	4.25	2.50	3.68	1.05	3.30	-2.91	-0.36	8.24	8.62	9.61
Total Assets (Crs)	82.82	79.40	85.53	87.37	94.68	107	106	153	145	189
ROIC (%)	16.96	12.26	16.68	5.07	8.94	5.99	46.59	19.39	16.38	13.49
Op Profit after Taxes (Crs)	7.06	5.09	6.77	2.10	4.58	2.92	20.72	11.56	11.57	13.24
Invested Capital (Crs)	41.64	41.56	40.61	41.37	51.21	48.71	44.47	59.60	70.64	98.20
ROE (%)	16.89	9.05	11.75	3.24	9.23	-8.89	-1.12	17.11	13.87	13.43
Net Profit Margin (%)	4.13	3.51	3.89	1.00	3.03	-3.06	-0.40	5.06	5.14	5.09
Asset Turnover ratio	1.24	0.90	1.11	1.21	1.15	0.89	0.85	1.06	1.16	1.00
Equity Multiplier	3.29	2.87	2.73	2.69	2.65	3.27	3.27	3.18	2.33	2.64
Adjusted EPS	4.99	2.94	4.33	1.24	3.88	-3.43	-0.43	8.40	7.50	8.37
Valuation Ratios
P/E	7.19	11.33	13.54	35.91	8.69	0.00	0.00	15.68	6.94	15.48
Price to Book	1.21	1.02	1.59	1.16	0.80	0.31	0.51	2.79	0.96	2.08
EV/EBITDA	5.40	6.53	6.59	6.57	5.68	8.39	6.98	8.09	4.54	8.95
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Quarterly Results

Parnax Lab Ltd.
Sotac Pharmaceutical
Loading...
Lactose India
Loading...

In Rs. Cr.	Dec'22	Mar'23	Jun'23	Sep'23	Dec'23	Mar'24	Jun'24	Sep'24	Dec'24	Mar'25
Net Sales	46.82	40.91	48.74	42.61	50.99	46.37	50.12	48.36	40.22	49.04
Operating Expenses	39.45	36.17	42.25	37.33	45.02	40.57	41.50	41.12	35.94	42.41
Increase/Decrease in Stock	-0.52	-0.19	0.33	-1.71	0.82	-2.06	-0.17	3.00	-1.79	0.16
Raw Material	26.34	21.78	26.93	22.92	29.06	25.82	23.31	21.52	23.29	25.74
Employee Cost	5.15	5.30	5.68	5.76	5.81	6.47	6.42	6.12	5.67	6.22
Selling and Distribution Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Electricity, Power & Fuel Cost	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gen_AdminExpenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Miscellaneous Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Profit	7.38	4.74	6.50	5.29	5.97	5.80	8.62	7.24	4.27	6.63
Other Income	0.08	0.27	0.24	0.22	0.10	0.25	0.11	0.95	0.19	0.43
Interest	1.30	1.19	1.16	1.43	1.35	1.41	1.50	1.39	1.23	1.28
PBDT	6.16	3.82	5.58	4.08	4.72	4.63	7.23	6.81	3.23	5.78
Depreciation and Amortization	1.74	1.59	1.60	1.74	1.78	1.84	1.83	1.94	1.78	1.83
Profit Before Tax	4.42	2.23	3.98	2.34	2.94	2.79	5.40	4.87	1.45	3.95
Tax	1.26	0.79	0.65	0.47	0.76	0.55	1.42	1.46	0.23	1.03
Profit After Tax	3.16	1.44	3.33	1.87	2.18	2.25	3.99	3.41	1.21	2.92
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	3.15	1.44	3.32	1.87	2.18	2.24	3.98	3.41	1.21	2.92
Quarterly Ratios
EPS	3.70	1.25	2.89	1.63	1.89	1.95	3.46	2.97	1.05	2.54
Operating Profit Margin	15.75	11.58	13.33	12.40	11.71	12.50	17.19	14.97	10.63	13.52
Net Profit Margin	6.74	3.52	6.83	4.39	4.27	4.84	7.95	7.06	3.02	5.96

Reverse DCF

Earnings

Discount Rate (%)

Terminal Multiple

5 YEAR

10 YEAR

20 YEAR

10.00%

Implied Growth Rate over a 5 year period*

-0.50%

Implied Growth Rate over a 10 year period*

-2.50%

Implied Growth Rate over a 20 year period*

*Implied Growth calculated using Newton-Raphson method.

Learn how to use Reverse DCF

FAQs on Parnax Lab Ltd. Financials

How strong is Parnax Lab balance sheet?

Balance sheet of Parnax Lab is moderately strong, But short term working capital might become an issue for this company.

Is the debt of Parnax Lab increasing or decreasing?

The net debt of Parnax Lab is decreasing.
Latest net debt of Parnax Lab is ₹57.96 Crs as of Mar-25.
This is less than Mar-24 when it was ₹67.33 Crs.

Is the profitablity of Parnax Lab improving?

Yes, profit is increasing.
The profit of Parnax Lab is ₹11.54 Crs for TTM, ₹9.61 Crs for Mar 2024 and ₹8.62 Crs for Mar 2023.

Does Parnax Lab pay decent dividends?

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Parnax Lab latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Parnax Lab allocated its funds?

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

View FAQ's On Shareholding

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Parnax Lab Ltd.

Parnax Lab Ltd.

Has the share price of Parnax Lab grown faster than its competition?

Is Parnax Lab stock expensive?

How strong is Parnax Lab balance sheet?

Is the debt of Parnax Lab increasing or decreasing?

Is the profitablity of Parnax Lab improving?

Does Parnax Lab pay decent dividends?

How has Parnax Lab allocated its funds?

SIGN UP FOR FREE